THG-008

THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (rPARPi) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. The first clinical study for THG-008 is in head and neck cancers completed recruitment in May 2019 and a manuscript is currently in preparation for publication in a peer-reviewed journal.

Further clinical studies are currently in plan for other oncology indications to take THG-008 into Phase II.

THG-009

THG-009 is a novel iodine radiolabelled PARP inhibitor (rPARPi) which will soon enter clinical trials toward the development of this exciting product as a targeted radionuclide therapy. Details of our clinical development program for THG-009 will be released later in 2019.

THG-008

THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (rPARPi) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. The first clinical study for THG-008 is in head and neck cancers completed recruitment in May 2019 and a manuscript is currently in preparation for publication in a peer-reviewed journal.

Further clinical studies are currently in plan for other oncology indications to take THG-008 into Phase II.

THG-009

THG-009 is a novel iodine radiolabelled PARP inhibitor (rPARPi) which will soon enter clinical trials toward the development of this exciting product as a targeted radionuclide therapy. Details of our clinical development program for THG-009 will be released later in 2019.